Antiinflammatory Agent - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antiinflammatory Agent

The Experts below are selected from a list of 195 Experts worldwide ranked by ideXlab platform

C Yoshida – 1st expert on this subject based on the ideXlab platform

  • pharmacological studies on 3 formylamino 7 methylsulfonylamino 6 phenoxy 4h 1 benzopyran 4 one t 614 a novel Antiinflammatory Agent 4th communication inhibitory effect on the production of interleukin 1 and interleukin 6
    Journal of pharmacobio-dynamics, 1992
    Co-Authors: Keiichi Tanaka, Yukihiko Aikawa, Takihiro Inaba, Hiroki Kawasaki, Keiko Asaoka, C Yoshida

    Abstract:

    In vitro effects of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel Antiinflammatory compound, on the production of interleukin-1 (IL-1) and/or interleukin-6 (IL-6) by human monocytes and the THP-1 cells of a human monocytic cell line, were examined. T-614 inhibited the release of immunoreactive IL-1β from these cells stimulated with lipopolysaccharides (LPS) in a dose-dependent manner (0.3-30 μg/ml). The release of IL-6 from THP-1 cells, as detrmined by the assays for its hepatocyte-stimulating activities and immunoreactivities, was inhibited by T-614 with the IC50 values of 2.0 and 6.6 μg/ml, respectively. Northern blotting analysis using LPS-stimulated THP-1 cells indicated that the inhibitory effect of T-614 on IL-1β production is caused by the suppression of IL-1β mRNA expression. The inhibition of cytokine production by T-614 may provide an important insight into the additional mechanisms contributing to its Antiinflammatory activities.

  • pharmacological studies of the new Antiinflammatory Agent 3 formylamino 7 methylsulfonylamino 6 phenoxy 4 1 benzopyran 4 o ne 2nd communication effect on the arachidonic acid cascades
    Drug Research, 1992
    Co-Authors: Keiichi Tanaka, Shinji Makino, Tomoya Shimotori, Yukihiko Aikawa, Takihiro Inaba, C Yoshida

    Abstract:

    Abstract The in vitro and in vivo effects of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-on e (T-614, CAS 123663-49-0), a new Antiinflammatory Agent, on arachidonic acid metabolism were investigated in comparison with those of reference drugs. Although the inhibitory effect of T-614 on the synthesis of prostaglandins by rabbit renal microsomes was very weak (IC50 of 58 micrograms/ml), T-614 effectively inhibited the prostaglandin E2 (PGE2) generation by mouse fibroblasts stimulated with bradykinin with an IC50 value of 0.47 micrograms/ml. The suppressive effect of T-614 on the PGE2 generation in fibroblasts was also found when cells were stimulated with Ca ionophore A23187, but not when induced with arachidonic acid. T-614 suppressed the A23187-induced PGE2 generation by rat macrophages, but not the leukotriene B4 production. In addition, 5-lipoxygenase activities in guinea-pig peritoneal exudated cells were not inhibited. In in vivo experiments, at doses of more than 1 mg/kg, T-614 reduced the PGE2 contents in inflammatory exudate of rat carrageenin-sponge type inflammation, but it was almost inactive in inhibiting gastric prostaglandins production up to 100 mg/kg. T-614 also did not affect the urinary PGE2 excretion in rats, and slightly inhibited the thromboxane synthesis in rat blood. Furthermore, the convulsion-induced increase of PGE2 in mouse brain was inhibited by T-614. These data suggest that T-614 inhibits the production of cyclooxgenase-mediated products with apparently different mode from classical non-steroidal Antiinflammatory drugs, and may partly explain the discrepancy in pharmacological properties between this compound and other drugs.

  • pharmacological studies of the new Antiinflammatory Agent 3 formylamino 7 methylsulfonylamino 6 phenoxy 4h 1 benzopyran 4 o ne 1st communication Antiinflammatory analgesic and other related properties
    Drug Research, 1992
    Co-Authors: Keiichi Tanaka, C Yoshida, Shinji Makino, Tomoya Shimotori, Yukihiko Aikawa, Takihiro Inaba, Shuntaro Takano

    Abstract:

    The Antiinflammatory, analgesic and antipyretic activities of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614, CAS 123663-49-0) were investigated in various animal models and compared with those of nimesulide, indometacin and ibuprofen. The Antiinflammatory potency of T-614 on carrageenin-induced paw edema, paper disk granuloma and established adjuvant arthritis was greater than that of ibuprofen, but slightly lower than those of nimesulide and indometacin

Keiichi Tanaka – 2nd expert on this subject based on the ideXlab platform

  • pharmacological studies on 3 formylamino 7 methylsulfonylamino 6 phenoxy 4h 1 benzopyran 4 one t 614 a novel Antiinflammatory Agent 4th communication inhibitory effect on the production of interleukin 1 and interleukin 6
    Journal of pharmacobio-dynamics, 1992
    Co-Authors: Keiichi Tanaka, Yukihiko Aikawa, Takihiro Inaba, Hiroki Kawasaki, Keiko Asaoka, C Yoshida

    Abstract:

    In vitro effects of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel Antiinflammatory compound, on the production of interleukin-1 (IL-1) and/or interleukin-6 (IL-6) by human monocytes and the THP-1 cells of a human monocytic cell line, were examined. T-614 inhibited the release of immunoreactive IL-1β from these cells stimulated with lipopolysaccharides (LPS) in a dose-dependent manner (0.3-30 μg/ml). The release of IL-6 from THP-1 cells, as detrmined by the assays for its hepatocyte-stimulating activities and immunoreactivities, was inhibited by T-614 with the IC50 values of 2.0 and 6.6 μg/ml, respectively. Northern blotting analysis using LPS-stimulated THP-1 cells indicated that the inhibitory effect of T-614 on IL-1β production is caused by the suppression of IL-1β mRNA expression. The inhibition of cytokine production by T-614 may provide an important insight into the additional mechanisms contributing to its Antiinflammatory activities.

  • pharmacological studies of the new Antiinflammatory Agent 3 formylamino 7 methylsulfonylamino 6 phenoxy 4 1 benzopyran 4 o ne 2nd communication effect on the arachidonic acid cascades
    Drug Research, 1992
    Co-Authors: Keiichi Tanaka, Shinji Makino, Tomoya Shimotori, Yukihiko Aikawa, Takihiro Inaba, C Yoshida

    Abstract:

    Abstract The in vitro and in vivo effects of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-on e (T-614, CAS 123663-49-0), a new Antiinflammatory Agent, on arachidonic acid metabolism were investigated in comparison with those of reference drugs. Although the inhibitory effect of T-614 on the synthesis of prostaglandins by rabbit renal microsomes was very weak (IC50 of 58 micrograms/ml), T-614 effectively inhibited the prostaglandin E2 (PGE2) generation by mouse fibroblasts stimulated with bradykinin with an IC50 value of 0.47 micrograms/ml. The suppressive effect of T-614 on the PGE2 generation in fibroblasts was also found when cells were stimulated with Ca ionophore A23187, but not when induced with arachidonic acid. T-614 suppressed the A23187-induced PGE2 generation by rat macrophages, but not the leukotriene B4 production. In addition, 5-lipoxygenase activities in guinea-pig peritoneal exudated cells were not inhibited. In in vivo experiments, at doses of more than 1 mg/kg, T-614 reduced the PGE2 contents in inflammatory exudate of rat carrageenin-sponge type inflammation, but it was almost inactive in inhibiting gastric prostaglandins production up to 100 mg/kg. T-614 also did not affect the urinary PGE2 excretion in rats, and slightly inhibited the thromboxane synthesis in rat blood. Furthermore, the convulsion-induced increase of PGE2 in mouse brain was inhibited by T-614. These data suggest that T-614 inhibits the production of cyclooxgenase-mediated products with apparently different mode from classical non-steroidal Antiinflammatory drugs, and may partly explain the discrepancy in pharmacological properties between this compound and other drugs.

  • pharmacological studies of the new Antiinflammatory Agent 3 formylamino 7 methylsulfonylamino 6 phenoxy 4h 1 benzopyran 4 o ne 1st communication Antiinflammatory analgesic and other related properties
    Drug Research, 1992
    Co-Authors: Keiichi Tanaka, C Yoshida, Shinji Makino, Tomoya Shimotori, Yukihiko Aikawa, Takihiro Inaba, Shuntaro Takano

    Abstract:

    The Antiinflammatory, analgesic and antipyretic activities of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614, CAS 123663-49-0) were investigated in various animal models and compared with those of nimesulide, indometacin and ibuprofen. The Antiinflammatory potency of T-614 on carrageenin-induced paw edema, paper disk granuloma and established adjuvant arthritis was greater than that of ibuprofen, but slightly lower than those of nimesulide and indometacin

Sumner Burstein – 3rd expert on this subject based on the ideXlab platform

  • Dimethylheptyl‐THC‐11 OIC acid: A nonpsychoactive Antiinflammatory Agent with a cannabinoid template structure
    Arthritis & Rheumatism, 1998
    Co-Authors: Robert B Zurier, Ronald G Rossetti, Joan H Lane, John M Goldberg, Sheila A Hunter, Sumner Burstein

    Abstract:

    Objective

    To assess the Antiinflammatory activity of dimethylheptyl-THC-11 oic acid (DMH-11C), a nonpsychoactive synthetic derivative of tetrahydrocannabinol.

    Methods

    Acute inflammation was induced by injection of interleukin-1β and tumor necrosis factor α into subcutaneous air pouches formed on the backs of mice. Inflammation was quantified 6 hours later by pouch fluid leukocyte counts. Adjuvant-induced polyarthritis in rats was used as a model of chronic inflammation and joint tissue injury. Animals were either untreated, treated with safflower oil, or treated with DMH-11C in safflower oil. Arthritis was assessed by clinical observation and by histomorphologic evaluation of tibiotarsal joints.

    Results

    Oral administration of DMH-11C reduced the accumulation of pouch fluid leukocytes and significantly reduced the severity of adjuvant-induced polyarthritis. Histopathologic studies of tibiotarsal joints showed that DMH-11C treatment attenuated pannus formation and joint tissue injury.

    Conclusion

    DMH-11C suppresses acute inflammation in the subcutaneous air pouch in mice and chronic joint inflammation characteristic of adjuvant disease in rats. These results demonstrate the potential use of this nonpsychoactive cannabinoid as an Antiinflammatory Agent.

  • dimethylheptyl thc 11 oic acid a nonpsychoactive Antiinflammatory Agent with a cannabinoid template structure
    Arthritis & Rheumatism, 1998
    Co-Authors: Robert B Zurier, Ronald G Rossetti, Joan H Lane, John M Goldberg, Sheila A Hunter, Sumner Burstein

    Abstract:

    Objective

    To assess the Antiinflammatory activity of dimethylheptyl-THC-11 oic acid (DMH-11C), a nonpsychoactive synthetic derivative of tetrahydrocannabinol.

    Methods

    Acute inflammation was induced by injection of interleukin-1β and tumor necrosis factor α into subcutaneous air pouches formed on the backs of mice. Inflammation was quantified 6 hours later by pouch fluid leukocyte counts. Adjuvant-induced polyarthritis in rats was used as a model of chronic inflammation and joint tissue injury. Animals were either untreated, treated with safflower oil, or treated with DMH-11C in safflower oil. Arthritis was assessed by clinical observation and by histomorphologic evaluation of tibiotarsal joints.

    Results

    Oral administration of DMH-11C reduced the accumulation of pouch fluid leukocytes and significantly reduced the severity of adjuvant-induced polyarthritis. Histopathologic studies of tibiotarsal joints showed that DMH-11C treatment attenuated pannus formation and joint tissue injury.

    Conclusion

    DMH-11C suppresses acute inflammation in the subcutaneous air pouch in mice and chronic joint inflammation characteristic of adjuvant disease in rats. These results demonstrate the potential use of this nonpsychoactive cannabinoid as an Antiinflammatory Agent.